P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
Nabin Raj Karki, Abdullah Kutlar Division of Hematology/Oncology, Augusta University, Augusta, GA, USACorrespondence: Nabin Raj KarkiDivision of Hematology Oncology, Georgia Cancer Center at Augusta University, 1410, Laney Walker Blvd, CN 5347, Augusta, GA, 30912, USATel +1-706-721-2505Fax +1-706-72...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-03-01
|
| Series: | Journal of Pain Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/p-selectin-blockade-in-the-treatment-of-painful-vaso-occlusive-crises--peer-reviewed-article-JPR |
| _version_ | 1818448764433596416 |
|---|---|
| author | Karki NR Kutlar A |
| author_facet | Karki NR Kutlar A |
| author_sort | Karki NR |
| collection | DOAJ |
| description | Nabin Raj Karki, Abdullah Kutlar Division of Hematology/Oncology, Augusta University, Augusta, GA, USACorrespondence: Nabin Raj KarkiDivision of Hematology Oncology, Georgia Cancer Center at Augusta University, 1410, Laney Walker Blvd, CN 5347, Augusta, GA, 30912, USATel +1-706-721-2505Fax +1-706-721-5566Email nkarki@augusta.eduAbstract: Microvascular vaso-occlusion driven pain crisis is the hallmark of sickle cell disease with profound morbidity and increased mortality. Selectins, most notably P-selectins have an integral role in this phenomenon. P-selection was first identified in 1989. In 2019, after 3 decades of basic, translational, and clinical work with this pathway, the US Food and Drug Administration approved a P-selectin antibody, crizanlizumab to reduce frequency of pain crisis in patients more than 16 years with sickle cell disease. We review the fundamentals of P-selectin pathobiology, P-selectin blocking agents, clinical data with the use of crizanlizumab and prospects of this novel class of drugs in the context of other treatments for painful vaso-occlusive episodes.Keywords: P-selectin, sickle cell disease, pain crisis, crizanlizumab |
| first_indexed | 2024-12-14T20:24:42Z |
| format | Article |
| id | doaj.art-53419f7a608440aeafa6d6f32835cf6f |
| institution | Directory Open Access Journal |
| issn | 1178-7090 |
| language | English |
| last_indexed | 2024-12-14T20:24:42Z |
| publishDate | 2021-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Pain Research |
| spelling | doaj.art-53419f7a608440aeafa6d6f32835cf6f2022-12-21T22:48:39ZengDove Medical PressJournal of Pain Research1178-70902021-03-01Volume 1484985663536P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on CrizanlizumabKarki NRKutlar ANabin Raj Karki, Abdullah Kutlar Division of Hematology/Oncology, Augusta University, Augusta, GA, USACorrespondence: Nabin Raj KarkiDivision of Hematology Oncology, Georgia Cancer Center at Augusta University, 1410, Laney Walker Blvd, CN 5347, Augusta, GA, 30912, USATel +1-706-721-2505Fax +1-706-721-5566Email nkarki@augusta.eduAbstract: Microvascular vaso-occlusion driven pain crisis is the hallmark of sickle cell disease with profound morbidity and increased mortality. Selectins, most notably P-selectins have an integral role in this phenomenon. P-selection was first identified in 1989. In 2019, after 3 decades of basic, translational, and clinical work with this pathway, the US Food and Drug Administration approved a P-selectin antibody, crizanlizumab to reduce frequency of pain crisis in patients more than 16 years with sickle cell disease. We review the fundamentals of P-selectin pathobiology, P-selectin blocking agents, clinical data with the use of crizanlizumab and prospects of this novel class of drugs in the context of other treatments for painful vaso-occlusive episodes.Keywords: P-selectin, sickle cell disease, pain crisis, crizanlizumabhttps://www.dovepress.com/p-selectin-blockade-in-the-treatment-of-painful-vaso-occlusive-crises--peer-reviewed-article-JPRp-selectinsickle cell diseasepain crisiscrizanlizumab |
| spellingShingle | Karki NR Kutlar A P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab Journal of Pain Research p-selectin sickle cell disease pain crisis crizanlizumab |
| title | P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab |
| title_full | P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab |
| title_fullStr | P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab |
| title_full_unstemmed | P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab |
| title_short | P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab |
| title_sort | p selectin blockade in the treatment of painful vaso occlusive crises in sickle cell disease a spotlight on crizanlizumab |
| topic | p-selectin sickle cell disease pain crisis crizanlizumab |
| url | https://www.dovepress.com/p-selectin-blockade-in-the-treatment-of-painful-vaso-occlusive-crises--peer-reviewed-article-JPR |
| work_keys_str_mv | AT karkinr pselectinblockadeinthetreatmentofpainfulvasoocclusivecrisesinsicklecelldiseaseaspotlightoncrizanlizumab AT kutlara pselectinblockadeinthetreatmentofpainfulvasoocclusivecrisesinsicklecelldiseaseaspotlightoncrizanlizumab |